TYRO3, which has been recently identified as a potential therapeutic target in urothelial carcinoma [53], has been identified as one of the seven commonly secreted proteins from GCT cell lines (Fig. 1C). This evidence concerns the gene TYRO3 and urothelial carcinoma.